)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Orgenesis
Orgenesis (ORGS) investor relations material
Orgenesis has been otc
Orgenesis Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary20 May, 2026
Executive summary
Special Meeting scheduled for May 27, 2026, to be held virtually, allowing shareholders to attend, vote, and submit questions online for increased participation and efficiency.
Key proposals include increasing authorized shares, approving a convertible loan agreement with potential share issuance, and ratifying the appointment of the independent auditor for 2025.
Board of Directors recommends approval of all proposals, emphasizing the need for additional capital and operational flexibility.
Voting matters and shareholder proposals
Proposal 1: Amend Articles of Incorporation to increase authorized common stock from 14,583,333 to 150,000,000 shares.
Proposal 2: Approve Convertible Loan Agreement with Alpha Prosperity Fund SPC, including potential issuance of up to 60,578,082 shares upon conversion and warrant exercise.
Proposal 3: Ratify Kesselman & Kesselman C.P.A.s as independent registered public accounting firm for fiscal year ending December 31, 2025.
Shareholders of record as of April 22, 2026, are eligible to vote; each share entitles the holder to one vote.
Advance notice requirements and universal proxy rules apply for shareholder proposals and director nominations for the 2026 Annual Meeting.
Board of directors and corporate governance
Board recommends voting FOR all proposals, citing corporate governance and operational needs.
Board approved the share increase on March 26, 2026, pending shareholder approval.
Board and management are responsible for proxy solicitation and oversight of the virtual meeting process.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Orgenesis
- Shareholders to vote on major share increase, convertible loan, and auditor ratification.ORGS
Proxy filing - Shareholders will vote on major share authorization, a convertible loan, and auditor ratification.ORGSProxy filing
- Severe liquidity issues and a $49M net loss raise substantial doubt about ongoing operations.ORGSQ4 2024
- Registering 2.48M shares for resale by advisors, with proceeds only from warrant exercises.ORGSRegistration Filing
- Revenue up 101% but liquidity and going concern risks persist after Nasdaq delisting.ORGSQ3 2024
- Revenue up, losses down, but urgent capital and Nasdaq compliance needed to avoid delisting.ORGSQ2 2024
Orgenesis
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Orgenesis Inc. is engaged in the development, manufacture, and commercialization of cell and gene therapies (CGTs) for diabetes and other serious chronic medical conditions. We are currently focused on developing a stem cell therapy-based treatment for patients with type 1 diabetes that do not produce insulin. Our product, “MAVENcell,” could potentially become the first non-immunosuppressive pancreatic islet cell transplantation therapy and lead to a cure for every individual who has lost their insulin producing ability. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.